PriceTargets.com logo

REGENXBIO - RGNX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $28.63
  • Forecasted Upside: 120.53%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$12.98 As of 12/4/2025 05:00 PM ET
▲ +0.1 (0.78%)

This chart shows the closing price for RGNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New REGENXBIO Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGNX

Analyst Price Target is $28.63
▲ +120.53% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for REGENXBIO in the last 3 months. The average price target is $28.63, with a high forecast of $52.00 and a low forecast of $12.00. The average price target represents a 120.53% upside from the last price of $12.98.

This chart shows the closing price for RGNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 contributing investment analysts is to moderate buy stock in REGENXBIO. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2025Chardan CapitalReiterated RatingBuy ➝ Buy$52.00
11/7/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$17.00 ➝ $19.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$34.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/8/2025Chardan CapitalReiterated RatingBuy ➝ Buy$52.00
9/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$34.00
8/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$34.00
8/8/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$21.00 ➝ $17.00
8/8/2025BarclaysLower TargetOverweight ➝ Overweight$50.00 ➝ $37.00
8/8/2025Chardan CapitalReiterated RatingBuy ➝ Buy$52.00
6/9/2025Chardan CapitalReiterated RatingBuy ➝ Buy$52.00
4/17/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$14.00 ➝ $12.00
3/20/2025Chardan CapitalReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
3/18/2025Leerink PartnersSet Target$24.00
3/17/2025HC WainwrightLower TargetBuy ➝ Buy$36.00 ➝ $34.00
3/14/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$22.00 ➝ $24.00
3/14/2025Chardan CapitalReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
2/11/2025The Goldman Sachs GroupDowngradeBuy ➝ Neutral$38.00 ➝ $14.00
2/7/2025Raymond James FinancialInitiated CoverageOutperform$27.00
2/6/2025Raymond James FinancialUpgradeModerate Buy
1/21/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
1/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
12/11/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$35.00 ➝ $35.00
11/21/2024HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $36.00
11/20/2024Chardan CapitalReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
11/15/2024Morgan StanleyReiterated RatingOverweight$22.00
11/7/2024HC WainwrightBoost TargetBuy ➝ Buy$39.00 ➝ $40.00
10/22/2024Chardan CapitalReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
10/10/2024Raymond James FinancialReiterated RatingOutperform$18.00
9/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$39.00 ➝ $39.00
8/5/2024BarclaysLower TargetOverweight ➝ Overweight$55.00 ➝ $50.00
8/5/2024HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $39.00
6/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
6/7/2024The Goldman Sachs GroupInitiated CoverageBuy$38.00
5/15/2024HC WainwrightBoost TargetBuy ➝ Buy$36.00 ➝ $38.00
4/12/2024Stifel NicolausReiterated RatingBuy ➝ Buy$40.00
3/11/2024HC WainwrightReiterated RatingBuy$36.00
3/8/2024Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform$20.00 ➝ $35.00
3/7/2024Chardan CapitalReiterated RatingBuy ➝ Buy$52.00
3/7/2024BarclaysBoost TargetOverweight ➝ Overweight$45.00 ➝ $55.00
3/6/2024Leerink PartnrsUpgradeMarket Perform ➝ Outperform
3/6/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$37.00
3/6/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$34.00 ➝ $39.00
2/28/2024WedbushReiterated RatingNeutral ➝ Neutral$21.00
2/21/2024Raymond James FinancialReiterated RatingOutperform$45.00
2/12/2024WedbushReiterated RatingNeutral ➝ Neutral$21.00
1/17/2024WedbushReiterated RatingNeutral$21.00
11/14/2023William BlairReiterated RatingNeutral$20.00 ➝ $21.00
11/1/2023Stifel NicolausInitiated CoverageBuy$35.00
10/5/2023WedbushReiterated RatingNeutral ➝ Neutral$20.00
10/4/2023Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$20.00
8/29/2023Morgan StanleyLower TargetOverweight ➝ Overweight$43.00 ➝ $42.00
8/3/2023Chardan CapitalReiterated RatingBuy$55.00
6/1/2023Robert W. BairdInitiated CoverageOutperform$42.00
5/4/2023Chardan CapitalLower Target$61.00 ➝ $55.00
3/6/2023Morgan StanleyLower TargetOverweight$50.00 ➝ $46.00
3/2/2023Chardan CapitalReiterated RatingBuy$61.00
1/23/2023Leerink PartnersLower TargetMarket Perform$15.00 ➝ $14.00
11/21/2022Morgan StanleyLower TargetOverweight$52.00 ➝ $50.00
11/4/2022Chardan CapitalLower TargetBuy$70.00 ➝ $61.00
11/4/2022Leerink PartnersBoost TargetMarket Perform$13.00 ➝ $14.00
10/4/2022WedbushLower TargetNeutral$32.00 ➝ $28.00
10/4/2022Royal Bank Of CanadaLower Target$47.00 ➝ $29.00
9/9/2022Morgan StanleyBoost TargetOverweight$46.00 ➝ $52.00
8/10/2022Morgan StanleyLower TargetOverweight$47.00 ➝ $46.00
7/11/2022WedbushReiterated RatingHold$29.00
6/23/2022Berenberg BankInitiated CoverageBuy$61.00
6/23/2022UBS GroupLower TargetBuy$51.00 ➝ $47.00
5/24/2022Morgan StanleyLower TargetOverweight$51.00 ➝ $47.00
4/11/2022Chardan CapitalReiterated RatingBuy
3/29/2022Chardan CapitalLower Target$90.00 ➝ $76.00
3/23/2022Morgan StanleyBoost TargetOverweight$50.00 ➝ $51.00
3/2/2022Leerink PartnersLower TargetMarket Perform$29.00 ➝ $25.00
2/10/2022Leerink PartnersLower TargetMarket Perform$35.00 ➝ $29.00
1/28/2022Leerink PartnersLower TargetMarket Perform$43.00 ➝ $35.00
12/15/2021WedbushInitiated CoverageNeutral$29.00
11/3/2021Chardan CapitalLower TargetBuy$100.00 ➝ $90.00
11/3/2021Leerink PartnersLower TargetMarket Perform$44.00 ➝ $43.00
10/25/2021Roth CapitalBoost TargetBuy$15.00 ➝ $17.00
10/12/2021Leerink PartnersReiterated RatingHold
9/14/2021Royal Bank Of CanadaBoost TargetSector Perform$50.00 ➝ $55.00
9/14/2021BarclaysBoost TargetOverweight$79.00 ➝ $82.00
8/10/2021Chardan CapitalReiterated RatingBuy$100.00
7/1/2021Chardan CapitalReiterated RatingBuy
3/8/2021Morgan StanleyLower TargetOverweight$67.00 ➝ $62.00
1/20/2021Royal Bank Of CanadaBoost TargetNeutral ➝ Sector Perform$42.00 ➝ $50.00
1/19/2021Morgan StanleyBoost TargetOverweight$51.00 ➝ $67.00
1/6/2021Leerink PartnersBoost TargetMarket Perform$34.00 ➝ $37.00
1/6/2021Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$60.00
12/15/2020UBS GroupInitiated CoverageBuy$57.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 25 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 11 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 15 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 8 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 7 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 7 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

REGENXBIO logo
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $12.98
Low: $12.82
High: $13.77

50 Day Range

MA: $11.82
Low: $9.65
High: $13.62

52 Week Range

Now: $12.98
Low: $5.03
High: $13.93

Volume

940,807 shs

Average Volume

583,994 shs

Market Capitalization

$657.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of REGENXBIO?

The following Wall Street sell-side analysts have issued stock ratings on REGENXBIO in the last twelve months: Barclays PLC, Chardan Capital, HC Wainwright, Leerink Partners, Morgan Stanley, Raymond James Financial, Inc., Royal Bank Of Canada, The Goldman Sachs Group, Inc., Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for RGNX.

What is the current price target for REGENXBIO?

0 Wall Street analysts have set twelve-month price targets for REGENXBIO in the last year. Their average twelve-month price target is $28.63, suggesting a possible upside of 120.5%. Chardan Capital has the highest price target set, predicting RGNX will reach $52.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $12.00 for REGENXBIO in the next year.
View the latest price targets for RGNX.

What is the current consensus analyst rating for REGENXBIO?

REGENXBIO currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RGNX.

What other companies compete with REGENXBIO?

Other companies that are similar to REGENXBIO include Apellis Pharmaceuticals, Bausch Health Cos, Beam Therapeutics, Terns Pharmaceuticals and HUTCHMED. Learn More about companies similar to REGENXBIO.

How do I contact REGENXBIO's investor relations team?

REGENXBIO's physical mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is (240) 552-8181 and its investor relations email address is [email protected]. The official website for REGENXBIO is www.regenxbio.com. Learn More about contacing REGENXBIO investor relations.